Omnicell Q4 revenue rises 19% to $307 million; full-year revenue falls 3% to $1.112 billion
Omnicell reported fourth-quarter 2024 revenue of $307 million, up 19% from a year earlier, and GAAP net income of $16 million, compared with a loss of $14 million in the prior-year quarter. For the full year, revenue fell 3% to $1.112 billion and non-GAAP earnings per diluted share fell to $1.71 from $1.91, so shareholders see a mixed picture. The company also gave 2025 guidance for total revenue of $1.105 billion to $1.155 billion and non-GAAP earnings per share of $1.65 to $1.85.
Key points
- Q4 2024 total revenue was $307 million, up $48 million, or 19%, from Q4 2023; full-year revenue was $1.112 billion, down $35 million, or 3%.
- Full-year 2024 GAAP net income was $13 million, or $0.27 per diluted share, versus a GAAP net loss of $20 million in 2023.
- Full-year 2024 non-GAAP net income was $79 million, or $1.71 per diluted share, versus $87 million, or $1.91, in 2023; non-GAAP EBITDA was $136 million versus $138 million.
- 2025 guidance: total revenue of $1.105 billion to $1.155 billion and non-GAAP EBITDA of $140 million to $155 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.